tPA for acute stroke: balancing baseline imbalances
J Mann - CMAJ, 2002 - Can Med Assoc
1. Kappel J, Calissi P. Nephrology: 3. Safe drug prescribing for patients with renal
insufficiency. CMAJ 2002; 166 (4): 473-7. 2. Osborne R, Joel S, Grebenik K, Trew D, Slevin …
insufficiency. CMAJ 2002; 166 (4): 473-7. 2. Osborne R, Joel S, Grebenik K, Trew D, Slevin …
[HTML][HTML] Should Physicians Give Tpa to Patients with Acute Ischemic Stroke?: For: Thrombolytics in stroke: whose risk is it anyway?
DJ Robinson - Western Journal of Medicine, 2000 - ncbi.nlm.nih.gov
Stroke remains the leading cause of long-term disability in the United States. One third of
stroke patients presenting with severe disabilities cannot care for themselves. By 7 years …
stroke patients presenting with severe disabilities cannot care for themselves. By 7 years …
The stroke-thrombolytic predictive instrument provides valid quantitative estimates of outcome probabilities and aids clinical decision-making
BM Demaerschalk - Stroke, 2006 - Am Heart Assoc
Computerized clinical decision support systems are increas-ingly popular in health sciences
and have been demonstrated to improve practitioner performance. 1 For an emergency …
and have been demonstrated to improve practitioner performance. 1 For an emergency …
Detriments of tPA for acute stroke in routine clinical practice.(Patient Oriented Evidence that Matters).
BL Novak, RW Force - Journal of Family Practice, 2003 - go.gale.com
* BACKGROUND What are the benefits and harms of tPA in routine clinical practice?
Thrombolytic agents have been used in acute stroke to limit the progression of ischemia …
Thrombolytic agents have been used in acute stroke to limit the progression of ischemia …
Intravenous TPA for ischemic stroke patients: Houston experience 1996–2000
40 Background: Implementation of intravenous (IV) tissue plasminogen activator (TPA)
therapy with the NINDS protocol has been reported with variable safety. Our center has an …
therapy with the NINDS protocol has been reported with variable safety. Our center has an …
Can multivariable risk-benefit profiling be used to select treatment-favorable patients for thrombolysis in stroke in the 3-to 6-hour time window?
DM Kent, HP Selker, R Ruthazer, E Bluhmki, W Hacke - Stroke, 2006 - Am Heart Assoc
Background and Purpose—The Stroke-Thrombolytic Predictive Instrument (Stroke-TPI) uses
multivariate equations to predict outcomes with and without thrombolysis. We sought to …
multivariate equations to predict outcomes with and without thrombolysis. We sought to …
[HTML][HTML] Thrombolysis in acute stroke–Authors' reply
5 Lorenzano S, Ahmed N, Falcou A, et al. Does sex influence the response to intravenous
thrombolysis in ischemic stroke? Answers from safe implementation of treatments in Stroke …
thrombolysis in ischemic stroke? Answers from safe implementation of treatments in Stroke …
Thrombolytic therapy for ischemic stroke: from clinical trials to clinical practice
JP Mohr - Jama, 2000 - jamanetwork.com
INTRAVENOUS TISSUE-TYPE PLASMINOGEN ACTIVATOR (TPA) for ischemic stroke has
broken a major therapeutic bar-rier, and much more progress is certain to follow. Steadily …
broken a major therapeutic bar-rier, and much more progress is certain to follow. Steadily …
TPA use for stroke in the Registry of the Canadian Stroke Network
Background: Thrombolytic therapy with recombinant tissue plasminogen activator (tPA) has
been shown to be cost-effective and safe. Thrombolysis for stroke with tPA is now a standard …
been shown to be cost-effective and safe. Thrombolysis for stroke with tPA is now a standard …
Thrombolytic therapy for acute ischemic stroke: a very great honor
PD Lyden - Stroke, 2019 - Am Heart Assoc
2598 Stroke September 2019 investigators at 3 stroke centers examined the safety and
clinical outcome following treatment with escalating doses of intravenous single-chain tPA …
clinical outcome following treatment with escalating doses of intravenous single-chain tPA …